Biodesix Inc (BDSX)

Currency in USD
26.630
+2.600(+10.82%)
Closed·
27.150+0.520(+1.95%)
·
Advertisement
Unusual trading volume
Trading near 52-week High
BDSX is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
24.11027.105
52 wk Range
5.26027.105
Key Statistics
Prev. Close
24.03
Open
24.25
Day's Range
24.11-27.105
52 wk Range
5.26-27.105
Volume
274.23K
Average Volume (3m)
85.42K
1-Year Change
193.67%
Book Value / Share
0.88
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
BDSX Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
34.000
Upside
+27.68%
Members' Sentiments
Bearish
Bullish
ProTips
High return over the last year

Biodesix Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Strong Buy

Analyst Ratings

7 Buy
0 Hold
0 Sell
Ratings:
7 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 34.000
(+27.68% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
Canaccord
Buy35.00+31.43%27.00Maintain10/08/2026
Roth/MKM
Buy32.00+20.17%-New Coverage24/06/2026
Canaccord
Buy27.00+1.39%22.00Maintain18/06/2026
H.C. Wainwright
Buy26.00-2.37%-New Coverage15/06/2026
Canaccord
Buy22.00-17.39%20.00Maintain05/05/2026

Biodesix Inc Earnings Call Summary for Q2/2026

  • Biodesix Q2 2026 revenue rose 34% YoY to $26.9M, beating $25.93M estimate; shares fell 5% after-hours despite the beat.
  • Diagnostic testing revenue jumped 42% to $25.4M; gross margin reached 82%, up 200 bps YoY, marking fifth consecutive quarter above 80%.
  • Net loss narrowed 37% to $7.3M; adjusted EBITDA loss improved 56% to $3.2M as operating expenses rose only 7% versus 34% revenue growth.
  • Company maintained FY 2026 guidance of $108M-$114M revenue, implying slower H2 growth of 16%-22% versus strong first-half performance.
  • Management expects 80%+ gross margins to continue; plans to add 6-8 sales reps quarterly, reaching ~120 by year-end to drive adoption.
Last Updated: 05/08/2026, 22:12
Read Full Transcript

Earnings

Latest Release
05/08/2026
EPS / Forecast
-0.71 / -0.90
Revenue / Forecast
26.9M / 25.96M
EPS Revisions
Last 90 days

Compare BDSX to Peers and Sector

Metrics to compare
BDSX
Peers
Sector
Relationship
P/E Ratio
−10.1x−6.5x−0.4x
PEG Ratio
−0.23−0.240.00
Price/Book
30.7x7.1x2.6x
Price / LTM Sales
2.7x4.3x3.1x
Upside (Analyst Target)
25.8%4.5%48.9%
Fair Value Upside
Unlock−5.2%6.2%Unlock

Biodesix, Inc. operates as a diagnostic solutions company. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests markets as Nodify Lung Nodule Risk Assessment testing to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules. It also provides GeneStrat ddPCR, GeneStrat NGS, and VeriStrat tests markets as part of IQLung testing strategy, which are used in the diagnosis of lung cancer to measure the presence of mutations in the tumor and the state of the patient’s immune system to guide treatment decisions. In addition, the company provides diagnostic solutions, including translational research, initial biomarker discovery, assay design, development and validation, testing of clinical trial samples, regulatory, reimbursement, commercialization, and logistical support services for biopharmaceutical, life sciences, and diagnostic companies. Further, it operates laboratories. The company was formerly known as Elston Technologies, Inc. and as changed to Biodesix, Inc. in 2006. Biodesix, Inc. was incorporated in 2005 and is headquartered in Louisville, Colorado.

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
882.83K8.37%23.51M
Other Institutional Investors
4.62M43.82%123.12M
Public Companies & Retail Investors
5.04M47.81%134.35M
Total
10.55M100.00%280.98M

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
Aigh Capital Management, LLC6.43%678,32818,064
Soleus Capital Management, L.P.5.55%585,95815,604

People Also Watch

16.830
RLYB
+1.39%
5.08
PACK
+0.59%
2.76
RAY
-2.13%
7.8500
AKTX
+0.77%
29.12
AVBP
-0.21%

FAQ

What Is the Biodesix (NASDAQ: BDSX) Share Price Today?

The Biodesix stock price today is 26.630 USD.

What Stock Exchange Does Biodesix (BDSX) Trade On?

Biodesix is listed and trades on the Nasdaq Stock Exchange.

What Is the Ticker (Stock Symbol) for Biodesix?

The stock symbol (also called a 'ticker') for Biodesix is "BDSX."

What Is the Current Biodesix Market Capitalisation?

As of today, Biodesix (NASDAQ: BDSX) market cap is 280.980M USD.

What Is Biodesix's (BDSX) Earnings Per Share (TTM)?

The Biodesix EPS is currently -3.126 (Trailing Twelve Months).

When Is the Next Biodesix Earnings Date?

Biodesix's next earnings report will be released on 30/10/2026.

Is BDSX a Buy or Sell From a Technical Analyst Perspective?

Based on today's Biodesix moving averages and other technical indicators, the daily buy/sell signal for BDSX stock is Strong Buy.

How Many Times Has Biodesix Stock Split?

Biodesix has split 1 times. (See the BDSX stock split history page for full effective split date and price information.)

How Many Employees Does Biodesix Have?

Biodesix has 334 employees, based on their latest Companies House report.

What is the current trading status of Biodesix (NASDAQ: BDSX)?

As of 23/08/2026, Biodesix (BDSX) is trading at a share price of 26.630 USD, with a previous close of 24.030 USD. The stock has fluctuated within a day range of 24.110 USD to 27.105 USD, while its 52-week range spans from 5.260 USD to 27.105 USD.

What Is Biodesix (BDSX) Price Target According to Analysts?

The average 12-month price target for Biodesix is 34.000 USD, with a high estimate of 40 USD and a low estimate of 27 USD. 7 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +27.68% Upside potential.

What Is the BDSX Premarket Price?

BDSX's last pre-market stock price is 25.390 USD. The pre-market share volume is 340.000, and the stock has decreased by 1.360, or 5.660%.

What Is the BDSX After Hours Price?

BDSX's last after hours stock price is 27.150 USD, the stock has decreased by 0.520, or 1.950%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.